Tags

Type your tag names separated by a space and hit enter

Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Semin Oncol. 2006 Apr; 33(2 Suppl 7):S8-12.SO

Abstract

For patients with hormone-receptor-positive breast cancer, the risk of relapse remains significant even after successfully completing 5 years of adjuvant tamoxifen. The use of tamoxifen beyond 5 years is not recommended, but the need to protect against relapse following tamoxifen is clear. The third-generation aromatase inhibitors offer a new approach to treating postmenopausal women with receptor-positive early stage breast cancer through the potent and specific systemic inhibition of estrogen synthesis. MA.17, a large, randomized, double-blind, placebo-controlled phase III study, investigated whether extended adjuvant therapy with letrozole following completion of around 5 years of standard tamoxifen therapy could prolong disease-free survival in postmenopausal women with hormone-receptor-positive or receptor-unknown early stage breast cancer. The updated analyses of the trial results (median follow-up, 2.5 years) confirm that letrozole significantly reduced the risk of recurrent breast cancer (42%) regardless of the patient's nodal status or receipt of prior chemotherapy, and significantly reduced the risk of distant metastasis (40%). Importantly, letrozole as extended adjuvant therapy achieved a significant improvement in overall survival in women with node-positive disease. Mortality was reduced by 39% among the approximately 2,500 women with node-positive disease randomized in the study. Letrozole showed minimal side effects compared with placebo; adverse effects on bone metabolism of uncertain clinical significance were the most noteworthy side effect. Thus, the updated results from the MA.17 trial support the previous findings and show extended adjuvant therapy with letrozole to be a well-tolerated protection against the continuing risk of breast cancer recurrence for thousands of women currently receiving standard adjuvant tamoxifen. The re-randomization of MA.17 patients to an additional 5 years of letrozole or to no treatment will provide further insights into the benefits and side effects of long-term treatment.

Authors+Show Affiliations

Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA. pegoss@interlog.com

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

16730271

Citation

Goss, Paul E.. "Preventing Relapse Beyond 5 Years: the MA.17 Extended Adjuvant Trial." Seminars in Oncology, vol. 33, no. 2 Suppl 7, 2006, pp. S8-12.
Goss PE. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol. 2006;33(2 Suppl 7):S8-12.
Goss, P. E. (2006). Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Seminars in Oncology, 33(2 Suppl 7), S8-12.
Goss PE. Preventing Relapse Beyond 5 Years: the MA.17 Extended Adjuvant Trial. Semin Oncol. 2006;33(2 Suppl 7):S8-12. PubMed PMID: 16730271.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. A1 - Goss,Paul E, PY - 2006/5/30/pubmed PY - 2006/7/11/medline PY - 2006/5/30/entrez SP - S8 EP - 12 JF - Seminars in oncology JO - Semin Oncol VL - 33 IS - 2 Suppl 7 N2 - For patients with hormone-receptor-positive breast cancer, the risk of relapse remains significant even after successfully completing 5 years of adjuvant tamoxifen. The use of tamoxifen beyond 5 years is not recommended, but the need to protect against relapse following tamoxifen is clear. The third-generation aromatase inhibitors offer a new approach to treating postmenopausal women with receptor-positive early stage breast cancer through the potent and specific systemic inhibition of estrogen synthesis. MA.17, a large, randomized, double-blind, placebo-controlled phase III study, investigated whether extended adjuvant therapy with letrozole following completion of around 5 years of standard tamoxifen therapy could prolong disease-free survival in postmenopausal women with hormone-receptor-positive or receptor-unknown early stage breast cancer. The updated analyses of the trial results (median follow-up, 2.5 years) confirm that letrozole significantly reduced the risk of recurrent breast cancer (42%) regardless of the patient's nodal status or receipt of prior chemotherapy, and significantly reduced the risk of distant metastasis (40%). Importantly, letrozole as extended adjuvant therapy achieved a significant improvement in overall survival in women with node-positive disease. Mortality was reduced by 39% among the approximately 2,500 women with node-positive disease randomized in the study. Letrozole showed minimal side effects compared with placebo; adverse effects on bone metabolism of uncertain clinical significance were the most noteworthy side effect. Thus, the updated results from the MA.17 trial support the previous findings and show extended adjuvant therapy with letrozole to be a well-tolerated protection against the continuing risk of breast cancer recurrence for thousands of women currently receiving standard adjuvant tamoxifen. The re-randomization of MA.17 patients to an additional 5 years of letrozole or to no treatment will provide further insights into the benefits and side effects of long-term treatment. SN - 0093-7754 UR - https://www.unboundmedicine.com/medline/citation/16730271/Preventing_relapse_beyond_5_years:_the_MA_17_extended_adjuvant_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0093-7754(06)00173-4 DB - PRIME DP - Unbound Medicine ER -